Member Info for Jarv55

We continue to rapidly progress the role out of our GS Money offerings and I look forward to providing further updates in due course."

I wonder if there will be a name change to GSmoneysend

Don't get the impression a leak is coming but tech wise the price has always bounced in this area. Lets see what Mr Cheeky can bring to the table, with his contacts he may surprise you.

Interesting shorts are slowly closing as the price is dropping on Spreadex.

Sorry you have such a high average if the Ceo comes across well tomorrow would you consider averaging down?

Slaker what price did you buy at? Personally see value down here.

I do tend to be conservative but here we go https://invst.ly/12gec-

I expect us to be hitting 1.60 today https://invst.ly/12ge9y

188star just washing through the last of the placing then we should get a good afternoon.

With offices now in London and Gdansk, it also serves the Ukrainian expat community and over 30 other European countries, with a current estimated yearly transaction volume of approximately €120 million, said GSTechnologies, which has agreed an option to acquire 60% of the share capital of EasySend.

Of this annual volume, 35% is derived from approximately 40,000 individual customers and 65% from approximately 350 active corporate customers.

GSTechnologies, which earlier this month raised £847,000 to accelerate its organic growth plans and for potential acquisitions, said it believes the acquisition would grow its customer base, in particular for its Angra Global payments and foreign exchange institution.

The deal would also provide access to additional technology, including EasySend's mobile terminal technology, said GSTechnologies chairman Tone Goh.

It is intended that EasySend's founders and management team will remain with the business and that the 40% minority holding will be retained by EasySend's founder.

News just gets better and better here building a solid company that will be making millions.

EasySend is a Financial Conduct Authority ("FCA") approved Authorised Payment Institution ("API"), conducting cross-border payment services. EasySend has a current estimated yearly transaction volume of approximately ?120 million, with 35% coming from approximately 40,000 individual customers and 65% from approximately 350 active corporate customers. GST believes the acquisition of a majority stake in EasySend would assist with growing the customer base for the Company's existing GS Money activities, in particular Angra Global, and provide access to additional technology, including EasySend's mobile terminal technology. It is intended that EasySend's founder and management team will remain with the business and that the 40% minority holding will be retained by EasySend's founder.

For more information on EasySend please see: https://www.easysend.pl/en/about-us

Completion of the Acquisition is conditional, inter alia, on final due diligence, the entering into of definitive sale and purchase documentation and also on GST obtaining approval from the FCA for the change of control of EasySend, a regulated entity. Further announcements will be made on the progress of the Acquisition in due course.

Tone Goh, Chairman of GST, Chairman of GST, commented: "We are very pleased to have reached an agreement with EasySend to acquire a majority stake in the business. Subject to the completion of our remaining due diligence, and the receipt of FCA approval, this acquisition will provide additional customers and technology to assist with the growth of our Angra Global business. We continue to rapidly progress the role out of our GS Money offerings and I look forward to providing further updates in due course."

Chief Executive Officer

genedrive

Sep 2023 - Present 3 months

Manchester, England, United Kingdom

Lead the development of Genedrive’s long and short term strategies. Responsible for the overall commercialisation of the products, driving profitability and improving the share price. Manage the overall operation and make major decisions affecting Genedrive. Manage Genedrive’s resources, negotiate or approve agreements and contracts.

See if he buys any shares after Thursday.

This was the update on the NICE website last week…

“ Following the committee meeting on 28 September 2023, the External Assessment Group (EAG) have completed further analyses as a result of points raised during the committee discussion. The next steps in the evaluation will be delayed to allow this analysis to be considered. The topic webpage will be updated with the revised timelines in due course.”

https://www.nice.org.uk/guidance/indevelopment/gid-dg10054

Just looking myself and apparently Nice are looking some evidence at the moment before carrying on so waiting on them to update the time line. Expect this will get covered in the Investor presentation on Thursday.

Https://healthinnovationmanchester.com/news/greater-manchester-diagnostics-innovation-programme-secures-over-14m-investment/

Posted on advfn and the Ceo used to work for Roche

hazl21 Nov '23 - 18:53 - 1733 of 1781

0 0 1

'The industry partners are as follows:

Diagnostic delivery partners include Sollis; Graphnet Health; Gendius; Jiva AI; Mindfield Advertising; By Gamers for Gamers; BCN Group.

The genomics project key partners are APIS Assay Technologies; EMQN CIC; Genedrive; Epinal; Chromition; and NW Genomic Medicine Alliance Service.

The diagnostics co-investment partners are AstraZeneca; Novartis; Boehringer-Ingelheim; MSD; Roche Diagnostics; MyCardium AI; Siemens; and Dedalus.

Funding from Innovate UK has been provided through Greater Manchester’s Innovation Accelerator programme. Led by Innovate UK on behalf of UK Research and Innovation, the pilot Innovation Accelerator programme is investing £100m in 26 transformative R&D projects to accelerate the growth of three high-potential innovation clusters – Glasgow City Region, Greater Manchester and West Midlands.'

Roger at a guess this is where he has picked the £14million from

hazl21 Nov '23 - 18:52 - 1732 of 1781

0 0 1

'A health innovation programme to advance the use of novel diagnostics across Greater Manchester has been boosted by over £6m investment from life sciences, digital and creative industry partners, as well as £7.7m from Innovate UK, the UK’s national innovation agency.

Over the next two years, the health innovation accelerator will focus on tackling some of the most challenging disease areas through early diagnosis using novel approaches and holistic treatment aligned to people’s specific needs. It is hoped this will help to save more lives and improve health outcomes for people at high risk or living in the most disadvantaged communities.

The £14m programme includes a range of projects in diagnosing liver disease, heart failure, lung cancer, chest pain and cardiometabolic conditions, as well as the ground-breaking DEVOTE programme, to deliver bedside genomic tests to prevent a second stroke in a patient who has experienced a stroke; rapid point of care devices to detect genetic changes; and the development of a ‘pharmacogenetic passport’ to improve the effectiveness and safety of medicines for patients.

The health innovation accelerator is delivered through a partnership between Health Innovation Manchester, Manchester University NHS Foundation Trust, and the University of Manchester.

Further partnerships with global organisations and SMEs in life sciences, digital and creative industries have also been secured to provide additional expertise in technology and analytics, diagnostics and genomics, user research and marketing. The novel approach to industry partnerships testament to the strength of the city-region’s existing collaborations with life sciences and digital businesses.'

He has an impressive CV https://uk.linkedin.com/in/james-cheek-6372838

For the longs worth a listen https://www.youtube.com/watch?v=g6ePGvdmlmw

Copper breaking out https://invst.ly/12g700